IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
GI (Part II)
This session will provide an overview of complex in vitro models specific to the Gastrointestinal tract and how they are being employed for ADME and leveraged for evaluation of alternative therapeutic modalities (T-cell therapy). Speakers will present on three case studies: 1) predicting absorption and intestinal first-pass elimination, 2) modeling oral phosphate prodrug bioconversion, and 3) safety evaluation of T cell-based therapies.
Date & Time
Thursday, November 14, 2024, 10:30 AM ET - 12:00 PM ET
Duration
90 minutes
Agenda
Welcome and Introduction
John Gleeson (Merck)
Abhinav Sharma (AbbVie)
Overview of GI CIVM/MPS for ADME
Abhinav Sharma (AbbVie)
Case Study: Prediction of absorption and intestinal first-pass elimination utilizing a human 3D intestinal microtissue
Stephanie Kourula (Johnson & Johnson)
Case Study: Modeling oral phosphate prodrug bioconversion
Abhinav Sharma (AbbVie)
Case Study: Employing a physiologically relevant 3D in vitro model for safety evaluation of T cell-based therapies
May Freag (Takeda)
Q&A / Discussion
John Gleeson (Merck)
Abhinav Sharma (AbbVie)
Moderators and Presenters
Abhinav Sharma, PhD
Senior Scientist - Translational Human Models Lead, Dermatology/Immunology Discovery
AbbVie
Abhinav joined AbbVie in 2020 after receiving a PhD in Chemical and Biological Engineering at University of Massachusetts Amherst where he developed in vitro models of human gut to study host-microbe interactions. In the current role he is leading efforts to establish MPS models of multiple organ systems for programs within AbbVie’s drug discovery and development pipeline.
John Gleeson, PhD
Associate Principal Scientist – Exploratory Biopharmaceutics
Merck & Co.
John Gleeson is an Associate Principal Scientist in Merck’s Pharmaceutical Science and Clinical Supply division. John joined Merck in 2020 after completing his PhD (UCD; Ireland) and Postdoctoral research (Cedars-Sinai Medical Center; CA and Carnegie Mellon University: PA). He supports the pre-clinical to clinical formulation development of oral programs and de-risks clinical bioperformance issues. John leads the development of clinically predictive intestinal absorption models using conventional and complex in vitro models.
Stephanie Kourula, PhD
Principal Scientist – Translational PK/PD Investigative Toxicology
Johnson & Johnson nnovative Medicine
Stephanie Kourula is a Principal Scientist in the Translational PK/PD Investigative Toxicology Department at Johnson & Johnson Innovative Medicine (J&J IM) in Belgium. After gaining a PhD in Pharmacology at the Martin-Luther University (Halle-Saale, Germany) and performing her postdoctoral research in the field of intestinal inflammation at Stanford University (USA) and at the Flemish Institute for Biotechnology (Belgium) she joined J&J IM in 2017. At J&J IM she is specialized in mechanism based drug disposition and organotypic models for translational ADME research.
May Freag, PhD
Senior Scientist – Investigative Toxicology
Takeda Pharmaceuticals
May Freag is a Senior Scientist in Investigative Toxicology within the Drug Safety Research and Evaluation Department at Takeda Pharmaceuticals. She joined Takeda in 2021 after completing her postdoctoral research in the field of biomedical engineering at Harvard Medical School. In her current role, May leads the development and integration strategy of advanced in vitro models including microphysiological systems (MPS) in oncology, with a particular focus on new modalities, including cell therapies and engagers.
